Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus(The University of Texas MD Anderson Cancer Center), Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center)
Cited by 67
Related Papers
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
|Journal of Biological Chemistry|2005|749
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
|American Journal of Hematology|2017|437
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
|Nature Communications|2020|383
Targeting HSP90 for cancer therapy
|British Journal of Cancer|2009|320